| Literature DB >> 17166639 |
P Mukherjee1, L B Pathangey, J B Bradley, T L Tinder, G D Basu, E T Akporiaye, S J Gendler.
Abstract
A MUC1-based vaccine was used in a preclinical model of colon cancer. The trial was conducted in a MUC1-tolerant immune competent host injected with MC38 colon cancer cells expressing MUC1. The vaccine included: MHC class I-restricted MUC1 peptides, MHC class II-restricted pan-helper-peptide, unmethylated CpG oligodeoxynucleotide, and granulocyte macrophage-colony stimulating factor. Immunization was successful in breaking MUC1 self-tolerance, and in eliciting a robust anti-tumor response. The vaccine stimulated IFN-gamma-producing CD4(+) helper and CD8(+) cytotoxic T cells against MUC1 and other undefined MC38 tumor antigens. In the prophylactic setting, immunization caused complete rejection of tumor cells, while in the therapeutic regimen, tumor burden was significantly reduced.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17166639 PMCID： PMC1810513 DOI： 10.1016/j.vaccine.2006.11.007
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641